Marc C. Huisman

In-human assessment of target engagement and blockade of radiolabeled BI 765063, an anti-SIRPα antibody

Johanna E. E. Pouw, Mirte Stavenga, Gerben J.C. Zwezerijnen, Khanum Ridler et autres

The signal regulatory protein alpha (SIRPα) receptor on myeloid cells binds cluster of differentiation (CD) antigen CD47 on tumor cells, resulting in a “don’t eat me” signal that inhibits phagocytosis. BI 765063, an anti-SIRPα antibody, may restore anti-tumor immunity by blocking this …

nl, de (code pays fourni par la source)

89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism

Marc C. Huisman, Johanna E. E. Pouw, Sandeep S.V. Golla, Damien G. Huglo et autres

BACKGROUND: Typically, tissue uptake, expressed in tissue over plasma ratio (TPR), is reported from a 89Zr-mAb PET study. Nonspecific antibody catabolism and the residualizing property of 89Zr hamper the use of tissue uptake as a measure for target mediated uptake. Therefore, we …

nl, fr, de, us (code pays fourni par la source)

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐ LAG ‐3 monoclonal antibody

Robin Michelet, Klas Petersson, Marc C. Huisman, C. Willemien Menke‐van der Houven van Oordt et autres

Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target …

nl, de (code pays fourni par la source)

Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by 18F-BMS-986192 PET: pooled analysis of data from four solid tumor types

Iris H.C. Miedema, Johanna E. E. Pouw, Anne Kwakman, Gerben J.C. Zwezerijnen et autres

Introduction Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using 18F-BMS-986192 positron emission tomography (PET)-imaging and looked for correlations with response and immune-related …

nl (code pays fourni par la source)

The development process of ‘fit-for-purpose’ imaging biomarkers to characterize the tumor microenvironment

Jakoba Johanna Eertink, Idris Bahce, John C. Waterton, Marc C. Huisman et autres

Immune-based treatment approaches are successfully used for the treatment of patients with cancer. While such therapies can be highly effective, many patients fail to benefit. To provide optimal therapy choices and to predict treatment responses, reliable biomarkers for the assessment of immune …

nl, gb, de (code pays fourni par la source)

Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET

Jessica E. Wijngaarden, Yvonne W. S. Jauw, Gerben J.C. Zwezerijnen, Berlinda J. de Wit–van der Veen et autres

Abstract Background Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the 89Zr-mAb uptake on PET. Target-specific binding in tumours is of main interest; however, non-specific irreversible uptake may also be present, which influences quantification. The aim …

nl (code pays fourni par la source)

How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans

Jessica E. Wijngaarden, Amina Ahbari, Johanna E. E. Pouw, Henri N. J. M. Greuter et autres

Abstract Background PET scans using zirconium-89 labelled monoclonal antibodies (89Zr-mAbs), known as 89Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of 89Zr-mAbs in the blood. Measuring activity concentrations in blood, however, requires invasive …

nl (code pays fourni par la source)

First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET

Johanna E. E. Pouw, Sayed M S Hashemi, Marc C. Huisman, Jessica E. Wijngaarden et autres

Background In patients with locally advanced unresectable non-small cell lung cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, has shown improved overall survival when used as consolidation therapy following concurrent chemoradiotherapy (CRT). However, it is unclear whether CRT itself upregulates …

nl (code pays fourni par la source)

89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs

Iris H.C. Miedema, Jessica E. Wijngaarden, Johanna E. E. Pouw, Gerben J.C. Zwezerijnen et autres

Introduction: 89Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([89Zr]Zr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune system. The measured uptake consists of target-specific and non-specific components, and it can be influenced by plasma availability of the …

nl, de (code pays fourni par la source)

Clinical validation of translational antibody PBPK model using tissue distribution data generated with 89Zr-immuno-PET imaging

Shufang Liu, Zhe Li, Marc C. Huisman, Dhaval K. Shah

us, nl (code pays fourni par la source)

Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Valentina Boni, Mary J. Fidler, Hendrik‐Tobias Arkenau, Alexander I. Spira et autres

Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Valentina Boni, Mary J. Fidler, Hendrik‐Tobias Arkenau, Alexander I. Spira et autres

Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial